Palantir Technologies closed Tuesday at $172.73 — down from the $179.94 high reported in Monday's note — and the more pointed story this week is that the pullback has arrived alongside a meaningful split in the peer group, where some names are still running while Palantir stalls.
The peer divergence is worth dwelling on. PATH added 6.9% on the week and GWRE gained 6.0%. NOW rose 6.3%. Against that backdrop, Palantir's flat-to-fractionally-positive one-week reading (roughly +0.7%) looks like relative underperformance, not consolidation. RBRK was the other laggard, shedding 7.9% over five sessions — so this is not a uniform sector rotation — but Palantir's inability to hold $180 when peers are still trending higher raises a question about whether the post-earnings multiple has found its natural ceiling.
The lending market reinforces the picture of a stock running out of tailwinds. Short interest is essentially unchanged at 3.05% of free float — flat for two weeks now, having dropped from roughly 90 million shares in mid-July to around 70 million and then stopped. The cover trade that drove the post-August 3 surge is finished. Availability remains extraordinarily loose, with over 1.8 billion shares available to borrow relative to roughly 70 million shorted, a ratio that removes any squeeze dynamic entirely. Cost to borrow has nudged higher this week, rising about 20% to 0.41%, but from a very low base — it is still firmly in "easy borrow" territory and the absolute level is not a signal. Options are similarly uninstructive: the put/call ratio at 0.98 sits almost exactly at its 20-day average, with a z-score near zero. The options market is not pricing a directional view either way.
On the Street, analyst targets set post-earnings remain well above the current print. Following the Q2 beat, UBS raised to $220, Mizuho to $215, and Citigroup to $245 — all maintaining positive ratings. Deutsche Bank upgraded to Buy on August 4. The consensus is bullish on direction, but the stock has retreated roughly $7 from where those targets were set, and the bear case has not gone away: a trailing P/E above 85x and a price-to-book near 26x leave little room for execution misses. EPS momentum factor scores remain strong (90th percentile on 30-day, 84th on 90-day), but forward earnings revisions are weak — the 12-month forward EPS growth rank sits at just the 14th percentile, a tension the bulls will need to resolve by November.
CEO Alex Karp has been selling consistently under his pre-arranged plan. On August 20 alone he disposed of roughly $23 million in shares across multiple tranches. The Chief Accounting Officer also sold small blocks on August 20 and 21. These are 10b5-1 plan sales rather than discretionary trades, so the significance is limited — but the 90-day net insider flow is a sell of nearly $97 million in value, a number that tends to weigh on sentiment when a stock is already struggling to hold a new high.
The next scheduled earnings date is November 2. Between now and then, the primary variable is whether the stock can attract a fresh incremental buyer at current multiples, or whether the peer group — which is still running — eventually catches up and the relative gap closes from above rather than below.
See the live data behind this article on ORTEX.
Open PLTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
